Mirtazapine augmentation in the treatment of refractory depression

Journal of Clinical Psychiatry

Volumn 60, Issue 1, 1999, Pages 45-49

  Carpenter, Linda L ^a   Jocic, Zeljko ^a   Hall, Joan M ^a   Rasmussen, Steven A ^a   Price, Lawrence H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONAZEPAM; DESIPRAMINE; FLUOXETINE; LEVOTHYROXINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; PAROXETINE; PERPHENAZINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG RESPONSE; DYSTHYMIA; FEMALE; HUMAN; HYPERSOMNIA; MALE; PRIORITY JOURNAL; SEDATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0032929950     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0110     Document Type: Article

References (16)

1. Anderson I, Tomenson B. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol (Oxf) 1994;8:238-249
2. Stahl SM. Are two antidepressant mechanisms better than one? [BRAINSTORMS] J Clin Psychiatry 1997;58:339-340
3. Thomas D, Nutt D, Holman R. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Br J Pharmacol 1992;106:430-434
4. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramme for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
5. Nierenberg A, Feighner J, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
6. de Montigny C, Haddjeri N, Mongeau P. The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs 1995;4(suppl 1):13-17
7. Cappiello A, McDougle C, Malison R, et al. Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry 1995;38:765-767
8. Pollack M, Hammerness P. Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry 1993;33:220-221
9. Sachs GS, Pollack MH, Brotman AW, et al. Enhancement of ECT benefit by yohimbine. J Clin Psychiatry 1986;47:508-510
10. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995;4(suppl 1):29-38
11. Summel G, Dopheide J, Stahl S. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17:10-21
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
14. deBoer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25
15. Davies R, Wilde M. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996;5:389-102
16. Stahl SM, Kremer C, Pinder R. Tolerability of mirtazapine used in high or low initial dose. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association: May 20, 1997; San Diego, Calif. Abstract NR242:133